Published in Gastric Cancer on January 01, 2003
Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 8.25
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer (1998) 3.81
Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res (2000) 3.32
Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet (1998) 3.01
Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res (1996) 2.81
A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol (1994) 2.02
5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med (1980) 1.95
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res (1999) 1.76
An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology (1999) 1.75
Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol (2001) 1.56
Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol (1989) 1.44
Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol (1998) 1.26
Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol (1994) 1.06
High-dose MTX/5-FU and adriamycin for gastric cancer. Semin Oncol (1983) 1.05
Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res (1995) 1.03
Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res (1999) 1.02
Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res (1986) 1.00
The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells. J Biol Chem (1981) 0.97
Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells. Int J Oncol (1999) 0.94
Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Cancer (1997) 0.90
Molecular targeting of mitomycin C chemotherapy. Int J Cancer (1997) 0.88
Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells. Anticancer Drugs (2001) 0.88
Overcoming CPT-11 resistance by using a biscoclaurine alkaloid, cepharanthine, to modulate plasma trans-membrane potential. Int J Cancer (1997) 0.85
O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives. Jpn J Cancer Res (2002) 0.83
An analysis of the therapeutic efficacy of protracted infusion of low-dose 5-fluorouracil and cisplatin in advanced gastric cancer. J Infect Chemother (2000) 0.82
Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter. Biochim Biophys Acta (2000) 0.81
Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers. Int J Oncol (2002) 0.77
Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumor cells. Int J Oncol (1997) 0.77
Unique action determinants of double acting topoisomerase inhibitor, TAS-103. Int J Oncol (2001) 0.77
Regulatory network of mitomycin C action in human colon cancer cells. Jpn J Cancer Res (1999) 0.76
Cancer immunoediting from immune surveillance to immune escape. Immunology (2007) 3.03
Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res (2006) 2.37
Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res (2006) 1.90
Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother Pharmacol (2002) 1.69
Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS trial. Ann Surg Oncol (2013) 1.66
Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer (2004) 1.58
Role of mitochondria as the gardens of cell death. Cancer Chemother Pharmacol (2005) 1.56
Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis (2003) 1.55
Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology (2006) 1.54
Decreased death from gastric cancer by endoscopic screening: association with a population-based cancer registry. Scand J Gastroenterol (2008) 1.52
Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein. Clin Cancer Res (2003) 1.50
Identification of functional hypoxia response elements in the promoter region of the DEC1 and DEC2 genes. J Biol Chem (2002) 1.48
A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors. Int J Clin Oncol (2005) 1.42
Normal values of echocardiographic parameters in relation to age in a healthy Japanese population: the JAMP study. Circ J (2008) 1.39
Normal range of left ventricular 2-dimensional strain: Japanese Ultrasound Speckle Tracking of the Left Ventricle (JUSTICE) study. Circ J (2012) 1.38
Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res (2005) 1.27
Annular geometry in patients with chronic ischemic mitral regurgitation: three-dimensional magnetic resonance imaging study. Circulation (2005) 1.25
Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem (2005) 1.25
Caspase-dependent and -independent cell death pathways after DNA damage (Review). Oncol Rep (2005) 1.24
Thoracoscopic-assisted repair of a bochdalek hernia in an adult: a case report. J Med Case Rep (2010) 1.24
Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer (2006) 1.21
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol (2013) 1.18
Long-term follow up of patients with multiple gastric carcinoids associated with type A gastritis. Gastric Cancer (2005) 1.15
Establishment of two cell lines from human gastric scirrhous carcinoma that possess the potential to metastasize spontaneously in nude mice. Cancer Sci (2004) 1.13
A single nucleotide polymorphism in the 5' untranslated region of the EGF gene is associated with occurrence and malignant progression of gastric cancer. Pathobiology (2005) 1.13
Difference in accuracy between gastroscopy and colonoscopy for detection of cancer. Hepatogastroenterology (2007) 1.11
Expression of hypoxia-inducible factor (HIF)-1alpha is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma. Eur J Cancer (2004) 1.10
Cavernous hemangioma of the rib. Ann Thorac Surg (2002) 1.10
Increased glycan chain length distribution and decreased susceptibility to moenomycin in a vancomycin-resistant Staphylococcus aureus mutant. Antimicrob Agents Chemother (2002) 1.10
Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J (2003) 1.09
Telomerase expression in noncancerous bronchial epithelia is a possible marker of early development of lung cancer. Cancer Res (2005) 1.08
CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep (2005) 1.05
Difference in prognostic significance of maximum standardized uptake value on [18F]-fluoro-2-deoxyglucose positron emission tomography between adenocarcinoma and squamous cell carcinoma of the lung. Jpn J Clin Oncol (2011) 1.04
Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. Anticancer Res (2004) 1.04
Expression of epiregulin, a novel epidermal growth factor ligand associated with prognosis in human oral squamous cell carcinomas. Oncol Rep (2008) 1.04
Single nucleotide polymorphism in the hypoxia-inducible factor-1alpha gene in colorectal carcinoma. Oncol Rep (2004) 1.01
Fluctuating liver functions in siblings with MPV17 mutations and possible improvement associated with dietary and pharmaceutical treatments targeting respiratory chain complex II. Mol Genet Metab (2009) 1.01
Association between Takayasu arteritis and ulcerative colitis - case report and review of serological HLA analysis. Med Sci Monit (2011) 1.00
The roles of surgical oncologists in the new era: minimally invasive surgery for early gastric cancer and adjuvant surgery for metastatic gastric cancer. Pathobiology (2011) 0.99
Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin Cancer Res (2004) 0.99
Neutrophil elastase induces cell proliferation and migration by the release of TGF-alpha, PDGF and VEGF in esophageal cell lines. Oncol Rep (2007) 0.97
Expression of TPX2 in salivary gland carcinomas. Oncol Rep (2009) 0.95
Moenomycin-resistance is associated with vancomycin-intermediate susceptibility in Staphylococcus aureus. Microbiol Immunol (2003) 0.95
Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses. Cancer Biol Ther (2005) 0.94
DNA methylation of genes linked to retinoid signaling in squamous cell carcinoma of the esophagus: DNA methylation of CRBP1 and TIG1 is associated with tumor stage. Cancer Sci (2005) 0.93
Current and future roles of neoadjuvant chemotherapy in operable breast cancer. Clin Breast Cancer (2005) 0.93
Esophageal reconstruction using the terminal ileum and right colon in esophageal cancer surgery. Surg Today (2011) 0.93
Left atrial volume and the risk of paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr (2004) 0.93
Development of a rapid culture method to induce adipocyte differentiation of human bone marrow-derived mesenchymal stem cells. Biochem Biophys Res Commun (2010) 0.92
Molecular mechanism of chemoresistance to cisplatin in ovarian cancer cell lines. Int J Mol Med (2004) 0.92
Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells. Cancer (2005) 0.92
A case of ascending aortic dissection and rupture caused by giant cell arteritis. Int Heart J (2014) 0.91
Advanced esophageal cancer with an esophago-bronchial fistula successfully treated by chemoradiotherapy following esophageal bypass surgery: report of a case. Surg Today (2012) 0.91
Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. Int J Oncol (2003) 0.91
Postgastrectomy Syndrome Assessment Scale (PGSAS)-45 and changes in body weight are useful tools for evaluation of reconstruction methods following distal gastrectomy. Ann Surg Oncol (2014) 0.90
A single nucleotide polymorphism in the MMP-1 promoter is correlated with histological differentiation of gastric cancer. J Cancer Res Clin Oncol (2004) 0.90
Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents. Surg Today (2004) 0.89
Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro. Pharmacogenet Genomics (2007) 0.89
Overexpression of the orotate phosphoribosyl-transferase gene enhances the effect of 5-fluorouracil on gastric cancer cell lines. Oncology (2007) 0.89
HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab. Anticancer Res (2005) 0.89
Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer (2004) 0.89
Selection of a novel drug-response predictor in esophageal cancer: a novel screening method using microarray and identification of IFITM1 as a potent marker gene of CDDP response. Int J Oncol (2008) 0.89
Reoperation for early failure of a freestyle bioprosthesis using a full root technique. J Heart Valve Dis (2007) 0.89
Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer. Oncology (2005) 0.88
Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis. Cancer Chemother Pharmacol (2014) 0.88
Clinical evaluation of novel interconnected porous hydroxyapatite ceramics (IP-CHA) in a maxillary sinus floor augmentation procedure. Dent Mater J (2012) 0.88
Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer (2006) 0.87
Left atrial volume in normal Japanese adults. Circ J (2006) 0.87
The role of apoptosis in cancer cell survival and therapeutic outcome. Cancer Biol Ther (2006) 0.86
Multidisciplinary approach to cancer treatment: a model for breast cancer treatment at the M.D. Anderson Cancer Center. Int J Clin Oncol (2004) 0.86
DNA hypermethylation and histone hypoacetylation of the HLTF gene are associated with reduced expression in gastric carcinoma. Cancer Sci (2003) 0.86
Quantitative prediction of tumor response to neoadjuvant chemotherapy in breast cancer: novel marker genes and prediction model using the expression levels. Breast Cancer (2011) 0.86
Differential regulation of DEC2 among hypoxia-inducible genes in endometrial carcinomas. Oncol Rep (2007) 0.86
[A case of rapid development of arc welder's lung during the course of a year]. Nihon Kokyuki Gakkai Zasshi (2003) 0.86
Quantitative detection of carcinoembryonic antigen messenger RNA in the peritoneal cavity of gastric cancer patients by real-time quantitative reverse transcription polymerase chain reaction. Anticancer Res (2003) 0.86
Immunobiology of the sentinel lymph node and its potential role for antitumour immunity. Lancet Oncol (2006) 0.85
Targeting of CD4+CD25high cells while preserving CD4+CD25low cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer. Int J Oncol (2009) 0.85
Differential gene expression profiles between neuroblastomas with high telomerase activity and low telomerase activity. J Pediatr Surg (2003) 0.85
Clinical evaluation of low-dose cisplatin and 5-fluorouracil as adjuvant chemoradiotherapy for advanced squamous cell carcinoma of the esophagus. Hiroshima J Med Sci (2005) 0.85
Characterization of cytochrome P450 expression in murine embryonic stem cell-derived hepatic tissue system. Drug Metab Dispos (2006) 0.85
Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer. Int J Oncol (2005) 0.85
Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo. Exp Cell Res (2011) 0.85
The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (review). Oncol Rep (2001) 0.85